Increased Drug Prices in the United States

The problem of rising drugs costs in the US has drawn attention from the general public, policymakers, and regulators in recent times. Pharmaceutical firms have hiked the cost of several prescriptions on a regular basis, which has put a heavy financial strain on government healthcare programs, healthcare providers, and consumers. This is because of the intricate interactions between R&D expenses, market dynamics, and healthcare economics. To lessen the effects of rising drug prices on all stakeholders, policies that support affordability, transparency, and competition in the pharmaceutical business are desperately needed (Tichy et al., 2023).

Statistics and Trends:

Concerns about US prescription drug prices rising have grown within the last ten years. The median annual cost of newly introduced prescription drugs increased from $1400 in 2008 to over $150,000 by 2021 (Angelis et al., 2023). In 2019, for example, Zolgensma drug approved for the treatment of spinal muscular atrophy became the most costly medication ever, costing nearly $2 million per dose (Starner & Gleason, 2019). Furthermore, a US government investigation from July 2022 to July 2022 found that 1216 products had average price rises of 31.6% over inflation (Angelis et al., 2023).

Reasons and Impacts of Increased Drug Prices:

Prescribed medication costs have increased due to a number of important variables. In order to present new treatments in healthcare setting, the drug manufacturers have to pay heavy charges for laboratory testing and drug production, including expenditure cost of clinical studies, FDA approval charges, patents filing and grant. Because of these high expenses, pharma business set prices that allow them to recover their investment and continue to fund research and development cost for new pharma products (Sertkaya et al., 2024). The changing conditions of the market are also quite important. Drug companies enjoy monopoly authority over prices due to their patent rights and market dominance, which restricts competitors that might otherwise end in price reductions. Amplified costs are a result of an absence of competitors for pharmaceuticals companies (Sertkaya et al., 2024).
Increasing medications have an effect on the entire society. Increased personal expenses are borne by both patients and customers, especially when it comes to medicinal products lacking generic alternatives. Stress related to money frequently results in failure to take medication, which worsens medical conditions and raises total medical expenses. Medical professionals attempt to strike an equilibrium between treating patients and expense reduction while navigating payment hurdles, involving healthcare facilities and payers (Sertkaya et al., 2024).

Conclusion:

Drug price inflation remains a multifaceted, intricate issue in the US, impacted by factors like as R&D costs, drug exclusivity, and rules and regulations. While improvements in healthcare quality and the development of therapeutic treatments depend heavily on breakthroughs in pharma creative thinking, resolving concerns about affordability and availability is equally important to ensuring that everybody can have fair access to essential pharmaceuticals.

Are you struggling to keep up with the demands of your academic journey? Don't worry, we've got your back!
Exam Question Bank is your trusted partner in achieving academic excellence for all kind of technical and non-technical subjects. Our comprehensive range of academic services is designed to cater to students at every level. Whether you're a high school student, a college undergraduate, or pursuing advanced studies, we have the expertise and resources to support you.

To connect with expert and ask your query click here Exam Question Bank